Technologies

Explore WARF Inventions and Patents

WARF Technologies

WARF’s portfolio of more than 1,700 technologies covers a wide range of categories, including analytical instrumentation, pharmaceuticals, food products, agriculture, research tools, medical devices, pluripotent stem cells, clean technology, information technology and semiconductors.

Information summaries, which describe each technology and its applications, benefits, inventors and patent status, can be downloaded, printed and shared by clicking on the technology category links to the left on this page.

Visit our subscription center to sign up for our monthly email updates and learn when new WARF technologies become available for licensing.

New Inventions

Analogs of Diptoindonesin G for Breast Cancer Drug Development

UW–Madison researchers have synthesized analogs of Dip G that have shown a greater ability than the parent molecule to decrease ERα expression and stabilize ERβ in cultured breast cancer cells. The compounds are active for ameliorating, attenuating and halting the growth/metastasis of breast cancers.
P170010US02

Physics ‘Office Hours’ educational learning platform

A physics education researcher at the University of Wisconsin-Green Bay has designed a novel and interactive app-based study aid platform for students in STEM disciplines. The platform’s interface is built around education research into how students conceptualize problems they do not understand. It is a novel tool to help students see why they are struggling with a particular problem, and what might help them solve it, rather than solving the problem for them. The team’s first working prototype, the Physics Office Hours app, has been designed for use in introductory-level college physics. The app is designed to mimic a scenario students might face during ‘office hours’ with a professor: Rather than offering an answer, the instructor guides the students through problems via a series of questions. A user-friendly online interface allows app content to be easily updated and changed over time and as more problem sets become available. In addition, the app architecture can easily be adapted to problem sets in other STEM disciplines and therefore serves as a platform technology.
T150035US01

Efficient In Vitro Assay for Antigen-Specific Tolerance

Building on their work, UW–Madison researchers have now developed a T cell-bound cytokine (T-CBC) assay for detecting and quantifying regulatory T cells specific to self-antigens or donor alloantigens. The new method comprises (a) culturing the subject’s T cells for 24 hours in the presence of one or more target antigens and (b) analyzing the cultured T cells for expression of a marker (EBi3; TGFβ/LAP) indicative of antigen-specific immune suppression.
P160186US02

Novel Transparent Dilatant Materials Comprised of Single Chemical Component

Research from the University of Wisconsin-Stevens Point has resulted in the synthesis of a series of materials exhibiting a range of dilatant properties. The materials show good transparency and are chemically uniform (e.g. consisting of a single chemical component). The degree of dilatancy is easily controlled by adjusting the compositions of the materials. Due to the range of dilatant properties, good transparency, and single chemical component nature of the dilatant samples, these materials show significant promise for novel uses in protective equipment and other areas related to impact protection, especially where transparency is desirable.
T170056US01

Rhinovirus-C Peptide for Development of Vaccines and Antivirals

UW–Madison researchers have identified novel immunogenic peptides from RV-C that are useful targets for therapeutic antibodies.

Recent advances in microscopy enabled the researchers to determine (with atomic resolution) the structure of an RV-C strain, both in its full, infectious form and as native empty particles. The structures highlighted immunogenic surfaces that could be used to design antivirals or vaccines against RV-C.
P160341US02
View More

New Patents

Faster, Higher Quality Medical Imaging

UW–Madison researchers have developed a reconstruction technique that uses a non-patient-specific signal model (e.g., a physical or physiological model) to improve image quality without compromising accuracy.

While other methods make use of such analytical models in the post-processing stage, the new technique utilizes the model earlier in the process, yielding clinically useful images from highly undersampled data. The reconstruction process is designed to accommodate deviations from the model when appropriate.
P150024US01

Yeast-Based Intein Platform for Drug Production

UW–Madison researchers have engineered non-self-cleaving Mxe GyrA inteins shown to significantly improve the production of fusion proteins from Saccharomyces cerevisiae. The novel inteins were developed through directed evolution, and they enhance fusion protein display (up to 3x) and secretion levels (up to 30x) compared to the wild type intein. The new yeast-based platform provides a robust alternative to bacterial intein expression systems.
P150056US02

Albumin-Free Protocol Cuts Cost, Supports Large-Scale Cardiomyocyte Production

UW–Madison researchers have developed a method for generating high yield, high purity cardiomyocytes/progenitors from PSCs under defined, albumin-free conditions. Their discovery that albumin is not necessary, and may even be deleterious, for cardiomyocyte differentiation dramatically reduces the cost of production.
P150011US02
View More